EnteroMedics has agreed to allow the use of a modified vBloc system for pre-clinical research by Galvani Bioelectronics, a joint venture between Verily Life Sciences and GlaxoSmithKline. Under the deal, an exclusive right of first negotiation will be obtained by Galvani for a prospective non-exclusive or exclusive supply of the system, while EnteroMedics will be paid for product development and will continue to have title, rights and ownership in the intellectual property for the modified system.
EnteroMedics, Verily-GSK joint venture enter partnership deal
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.